Skip to main content
. 2021 May 21;4(5):e2111113. doi: 10.1001/jamanetworkopen.2021.11113

Figure 2. Unadjusted Kaplan-Meier Survival Curves by Treatment Group for All Participants.

Figure 2.

The pembrolizumab-treated group had 2038 events and 771 censored patients (median survival, 11.4 [95% CI, 10.5-12.3] months); the platinum/pemetrexed–treated group, 4032 events and 1127 censored patients (median survival, 12.6 [95% CI, 12.0-13.1] months); the platinum/permetrexed/pembrolizumab–treated group, 1054 events and 371 censored patients (median survival, 12.9 [95% CI, 11.8-14.0] months); and the platinum/taxane–treated group, 7349 events and 2517 censored patients (median survival, 14.4 [95% CI, 13.9-14.9] months).